Overview

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This study evaluates addition of Vincristine Sulfate Liposome Injection (Marqibo®) to the standard regimen of Bendamustine and Rituximab in adult patients with indolent B-cell lymphoma. This is a dose-escalation study.

Phase:

Phase 1

Details

Lead Sponsor:

Adam Olszewski

Collaborators:

Rhode Island Hospital
Spectrum Pharmaceuticals, Inc
The Miriam Hospital

Treatments:

Bendamustine Hydrochloride
Rituximab
Vincristine